37 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
26 Mar 24
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
9:20am
to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether due to supply chain disruptions and the impact
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our
8-K
EX-99.1
3pamx2pecrw
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
n298ei yf
11 Dec 23
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
8:15am
8-K
EX-99.1
aklksi
16 Nov 23
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
8:00am
8-K
EX-99.1
9e6t33
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
EX-99.1
szb k2lmv
7 Nov 23
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
8:15am
8-K
EX-99.1
wxju1n0l9o txrb9
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
18872 tht7imla8xg24x
11 May 23
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
kk03lfun
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am
8-K
EX-99.1
j0xsn3v39 fl3
25 Oct 22
NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use
9:19am
8-K
EX-99.1
cx8infrygo5l6spz
14 Sep 22
Regulation FD Disclosure
8:30am